Journal article
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases
ML Hilbers, F Dimitriou, P Lau, P Bhave, GA McArthur, L Zimmer, K Kudura, CL Gérard, MP Levesque, O Michielin, R Dummer, PF Cheng, J Mangana
European Journal of Cancer | Published : 2021
Abstract
Background: Melanoma brain metastases (MBM) have a poor prognosis. Systemic treatments that have improved outcomes in advanced melanoma have been shown to have an intracranial (IC) effect. We studied the efficacy and outcomes of combined immune checkpoint inhibitor ipilimumab/nivolumab (Combi-ICI) or targeted therapy (Combi-TT) as first-line treatment in MBM. Methods: MBM patients treated with Combi-ICI or Combi-TT within 3 months after MBM diagnosis. Endpoints were progression-free survival (PFS) and overall survival (OS). Results: 53 patients received Combi-ICI, 32% had symptomatic MBM and 33.9% elevated LDH. 71.7% required local treatment. The disease control rate was 60.3%. IC response r..
View full abstractGrants
Awarded by Pfizer
Funding Acknowledgements
This research did not receive any specific grant from funding agencies in the public, commercial, or not-forprofit sectors. The melanoma registry database of the Department of Dermatology Zurich has been partially supported by an unrestricted grant to the University of Zurich from Amgen, Novartis, BMS, MSD and Pierre Fabre.